Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CAH stock price vs HUM: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HUM's multiple
Needs HUM P/E.
Implied fair value · at CAH's multiple
Needs CAH P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Cardinal Health, Inc. · implied price per share
Bear
$170.68
Base
$203.76
Bull
$246.84
HUMANA INC · implied price per share
Bear
$238.74
Base
$269.81
Bull
$310.28
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
MCKESSON CORP
CAH vs MCK
AmerisourceBergen Corporation
CAH vs ABC
Walgreens Boots Alliance, Inc.
CAH vs WBA
CVS Health Corporation
CAH vs CVS
HENRY SCHEIN INC
CAH vs HSIC
UNITEDHEALTH GROUP INC
CAH vs UNH
Elevance Health, Inc.
CAH vs ELV
Cigna Group
CAH vs CI
CENTENE CORP
CAH vs CNC
Oscar Health, Inc.
CAH vs OSCR
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CAH can stabilize revenue and improve margins toward HUM’s level, then the stock is worth holding or modestly adding to because the current price still sits below the implied P/E value; otherwise, the small 3.7% upside and weaker operating trend argue for patience rather than aggressive buying.
CAH trades at $230.03 versus an implied P/E price of $238.51, suggesting only 3.7% upside. That is a small gap and sits comfortably within the historical band of $207.03 to $253.03, so the valuation signal is not especially compelling on its own.
Supporting Metrics
